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Abstract Protein N glycosylation is an ancient posttrans-
lational modification that enriches protein structure and
function. The addition of one or more complex oligosac-
charides (glycans) to the backbones of the majority of
eukaryotic proteins makes the glycoproteome several orders
of magnitude more complex than the proteome itself.
Contrary to polypeptides, which are defined by a sequence
of nucleotides in the corresponding genes, glycan parts of
glycoproteins are synthesized by the activity of hundreds of
factors forming a complex dynamic network. These are
defined by both the DNA sequence and the modes of
regulating gene expression levels of all the genes involved
in N glycosylation. Due to the absence of a direct genetic
template, glycans are particularly versatile and apparently a
large part of human variation derives from differences in
protein glycosylation. However, composition of the indi-
vidual glycome is temporally very constant, indicating the
existence of stable regulatory mechanisms. Studies of
epigenetic mechanisms involved in protein glycosylation
are still scarce, but the results suggest that they might not
only be important for the maintenance of a particular
glycophenotype through cell division and potentially across
generations but also for the introduction of changes during
the adaptive evolution.
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Protein glycosylation
Protein glycosylation is an ubiquitous posttranslational
modification
Glycosylation is an ancient evolutionary protein modifica-
tion still existing in all three domains of life including
Archea, Bacteria and Eukarya (Calo et al. 2010; Weerapana
and Imperiali 2006). Over half of all known eukaryotic
proteins are N-glycosylated in a process starting with the
sequential addition of sugar molecules to the dolichol
pyrophosphate and followed by the transfer of a branched
structure (glycan) to asparagine residues within a sequence
Asn-X-Ser/Thr of a target protein (Apweiler et al. 1999).
The sequential formation of glycan structures occurs in the
endoplasmic reticulum by the enzymatic activity of trans-
ferases belonging to a gene family termed ALG, whereas a
transfer to a target protein is catalyzed by oligosaccharyl
transferase (Helenius and Aebi 2001) (Fig. 1). During their
passage through Golgi, N-glycans can further be modified
by core fucosylation, which primarily affects integrins
involved in cell–cell adhesion and motility (Potapenko et
al. 2010). Additionally, following proper protein folding,
glycan moieties can be modified by branching, which has
been related to receptor signalling (Partridge et al. 2004)
and cancer development (Dube and Bertozzi 2005).
Alternatively, glycans can be added to serine or
threonine residues in a process called O glycosylation.
Instead of being synthesized through a dolichol-based core
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acetylgalactosamine (GalNAc) to a protein creating a Tn
antigen (Ten Hagen et al. 2003), which can further be
converted into several different O-glycan structures includ-
ing sialyl Tn, Tantigen, sialyl Tand disialyl T (Dalziel et al.
2001; Potapenko et al. 2010). O glycosylation is an
essential modification of glycoconjugates called mucins,
which play a role in control of the immune response (V arki
and Angata 2006) and carcinogenesis (Hollingsworth and
Swanson 2004).
In this review, we will mainly focus on N glycosylation.
Its importance was indicated in a study where germline
deletion of a gene coding for an enzyme GPT (UDP-Glc-
NAc: dolichol phosphate N-acetylglucosamine-1-phosphate
transferase) that catalyzes the first step in the glycan
precursor biosynthesis leads to embryonic lethality in mice
(Marek et al. 1999). In unicellular organisms, glycans
generally function only as structural components of the cell
membrane, while in multicellular organisms they acquired
various complex functions needed to integrate numerous
cells into a single functional unit (Drickamer and Taylor
1998; V arki 1993).
Glycans are promising disease biomarkers
At least 2,000 different glycan determinants have been
found to exist in mammalian glycoproteins (Cummings
2009) and between two and five glycans are attached to a
single glycoprotein. This results in an exceedingly complex
glycoproteome (defined as the complete set of all glyco-
proteins in an organism), estimated to be at least several
orders of magnitude more complex than the proteome itself
(Lee et al. 2005). A typical glycan is a complex molecule
containing between 10 and 15 monosaccharides. Contrary
to proteins and DNA which are linear molecules, glycans
are nonlinear branched structures that are characterized not
only by the sequence of monomeric units but also by the
exact position of the glycosidic bond, its anomeric
configuration (α or β), the number of branches and the
position of branching.
Genealogy and biosynthetic pathways in the synthesis of
the glycan and the polypeptide parts of a glycoprotein are
different. Nevertheless once synthesized, glycoprotein
functions as a single unit with defined structural and
functional properties, which originates from both the
protein and the glycan moiety of the molecule (Skropeta
2009). The prominent peculiarity of the glycan moieties of
glycoproteins, contrary to the polypeptide moieties, is that
our genome does not contain genetic templates to code for
them. Instead, glycan structures result from the activity of a
dynamic network of over 600 “glycogenes” (Fig. 1)
(Taniguchi et al. 2002; Lauc et al. 2010) that code for
various glycosyltransferases, glycosidases, enzymes for
sugar nucleotide biosynthesis, transporters, etc. (Abbott et
al. 2008; Nairn et al. 2008). While the production of a
novel polypeptide structure requires a change in a DNA
sequence, which could have unfavourable effects on
genome stability, novel glycan structures could also be
resulting from a modulation of gene expression as well as a
change in the activity and/or the localization of any of the
enzymes involved in their production. Moreover, the
expression of “glycogenes” could be affected by various
transcription factors, Golgi organizers, proton pumps, etc.,
which additionally increases the number of genes and
protein products that are directly or indirectly involved in
the synthesis of glycans. Since these changes are liable to
environmental influences (Lauc and Zoldos 2010), they are
less predetermined than classical Mendelian mutations and
can lead to altered repertoire of glycan structures, as was
found in virtually all diseases (Alavi and Axford 2008;
Axford 1999; Brockhausen et al. 1998; Lebrilla and An
2009).
Even though the epigenetic effects pronounce the
complexity of glycan structures, there are also “classical”
mutations occurring in DNA leading to variability in glycan
synthesis. These rarely affect genes coding for core N-
glycan structure, but are more common in genes involved in
the production of glycan antennas, apparently causing a
large part of individual phenotypic variations that exist in
humans and other higher organisms. The majority of human
variability originates from single nucleotide polymorphisms
(SNPs). Individually, they do not manifest visible pheno-
types, but if present in specific combinations within the
same individual, they can have significant phenotypic
effects (Brown 2009; Dhiman et al. 2010; Ovsyannikova
et al. 2010). Due to the involvement of hundreds of genes
in glycan synthesis, glycosylation is particularly prone to
this type of variability. Some combinations of individual
SNPs can be manifested as specific glycophenotypes,
which might represent potential evolutionary advantages
or disadvantages. For example, various forms of congenital
Fig. 1 Glycans are not directly encoded in genes. While the structures
of proteins are directly encoded in their corresponding genes, the
structures of glycans are not predefined and result from dynamic
interactions of hundreds of proteins in the glycosylation pathway
426 Clin Epigenet (2011) 2:425–432disorders of glycosylation are caused by a combination of
several individual mutations (Freeze 2006). Each mutation
alone results in a decrease of enzyme activity, but when
combined in the same individual, they can result in a
complex phenotype associated with significant mortality
and extensive motoric, immunological, digestive and
neurological symptoms (Freeze 2002, 2006). Many of these
genes have been identified as important in dolichol-linked
oligosaccharide biosynthesis (Haeuptle and Hennet 2009).
Taking this into consideration, protein glycosylation may
represent by far the most complex and the most expensive
metabolic pathway in eukaryotes. In addition, since their
synthesis depends on both the presence of genetic poly-
morphisms and possible environmental changes, glycans
are very promising biomarkers.
Glycans are essential regulators of a number of different
biological processes
V ariations in glycosylation are of great physiological
significance since the altered glycan can significantly
change the structure and function of the whole glyco-
protein (Skropeta 2009). For example, proper glycosyla-
tion of Asn297 is essential for the pro-inflammatory
activity of immunoglobulin G (IgG) antibodies during
humoral immune response. The glycan moiety maintains
the IgG heavy chains in the proper conformation to bind
the Fc receptor Fcγ (Arnold et al. 2007). Consequently,
the enzymatic removal of this glycan significantly reduces
b i n d i n gt oa nF cr e c e p t o rF c γR and the pro-inflammatory
activity in vivo. Interestingly, its modification by sialyla-
tion reverses a pro-inflammatory effect of IgG into an anti-
inflammatory effect through a still unknown mechanism
(Anthony et al. 2008; Anthony and Ravetch 2010).
Therefore, knowledge of the exact glycan structure has a
significant impact on both normal immunoglobulin func-
tion in the immune response and during the intravenous
application of highly purified, polyclonal IgG antibodies
administered in cases of several autoimmune diseases
(Nimmerjahn and Ravetch 2008). However, glycan bind-
ing can also result in undesirable effects such as in the
case of fucose addition to the glycan core of IgG. Its
presence there interferes with IgG binding to FcγRIIIa
leading to an attenuated capacity to destroy invading cells
through antigen-dependent cell cytotoxicity (ADCC) activity.
T h ep r e s e n c eo fa ne x a c tg l y c a ns e e m st ob ee s s e n t i a li n
this process since IgG molecules lacking core fucose
were found to have an ADCC activity enhanced up to
50–100-fold (Shields et al. 2002). Importantly, IgG from
an endogenous serum seems to inhibit the antibody-
induced ADCC in therapeutic purposes by competing for
FcγRIIIa-binding sites (Preithner et al. 2006). However,
the removal of fucose from the therapeutic IgG resulted in
its higher affinity to bind FcγRIIIa and a better response
(Iida et al. 2006). Still, the therapeutic success will depend
on the ratio of core fucosylation on host versus the
administered IgGs. In a recent large population study, we
observed a range of non-core-fucosylated IgG in normal
population to be between 1.5% and 21% (manuscript in
preparation).
The biological activities of many other signalling and
receptor proteins (including Notch, GLUT4, NMDA recep-
tor, etc.) are also modulated by glycosylation, which
appears to be one of the main mechanisms for the adaptive
regulation of the cell surface in cell–cell adhesion and
cellular communication. Proper glycosylation of membrane
receptors is particularly important as it modulates adaptive
properties of the cell membrane and affects communication
between the cell and its environment (Dennis et al. 2009).
Deregulation of glycosylation is associated with a wide
range of diseases including cancer, diabetes, cardiovascular,
congenital, immunological and infectious disorders
(Crocker et al. 2007; Marth and Grewal 2008; Ohtsubo
and Marth 2006).
Epigenetic regulation affects glycan biosynthesis
Recently, we performed the first large-scale analysis of
human plasma glycome (defined as the complete set of
glycan structures in an organism), which revealed
unusually high variability in the level of individual
glycans in human plasma (Knežević et al. 2009). The
median difference between minimal and maximal levels of
individual plasma glycans was found to be over sixfold,
much more than recorded for any other class of macro-
molecules. Different measured personal and lifestyle
parameters (age, body mass index, smoking, etc.) were
found to explain only a small part of the observed
variability in the analyzed glycans (Knežević et al.
2010). In addition, the individual plasma glycome changes
very little even after prolonged period of time (Gornik et
al. 2009). All this argues in favour of the genetic
predetermination of the individual glycome composition
but also emphasizes the necessity to validate the impor-
tance of epigenetic factors that could play a role in
establishing a person’s glycome profile. Several clearly
identifiable glycophenotypes, which significantly differed
from the normal glycophenotype in levels of one or more
glycans, were observed to exist in both European and
Chinese populations. Some of these phenotypes were
associated with specific pathological conditions, while
others apparently did not have any identifiable adverse
consequences for health (Pučić et al. 2010). The heritability
of glycans is generally below 50% (Knežević et al. 2009),
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result of regulatory mechanisms, which maintain stable
regulation of protein glycosylation with time, but are not
necessarily heritable.
Since glycosylation is a very complex metabolic
process including hundreds of factors encoded by a large
group of “glycogenes” (Nairn et al. 2008), the structures
of final products, glycans, are not solely genetically
predefined (Fig. 2). Along with the importance of genetic
polymorphisms in establishing the variability of glycan
structures, much of the variance is resulting from a
complex network of interactions between competing
enzyme activities, supply of activated monosaccharide
donors (nucleotide sugars), transport through Golgi and
many other factors (Lauc et al. 2010). In addition, the
regulation of activity and structural localization of
hundreds of glycosyltransferases, glycosidases and other
enzymes is involved in the process. Stable epigenetic
regulation of expression of these “glycogenes” is an
obvious mechanism which can explain both the temporal
stability of the glycome in “normal” conditions and
specific changes which were reported to appear in various
diseases (Alavi and Axford 2008; Gornik and Lauc 2008).
A number of studies on epigenetic modifications involved
in protein glycosylation is still limited, but their results
indicate that this processi sv e r yi m p o r t a n tf o rt h e
regulation of protein glycosylation (Zoldoš et al. 2010).
Functional implications of epigenetic regulation
of protein glycosylation in cancer
Glycans participate in all major physiological events during
various stages of tumour progression, from tumour cell
proliferation, its dissociation from primary cancer and
dissemination through bloodstream, metastasis and angiogen-
esis (Fuster and Esko 2005; Potapenko et al. 2010;R e i se ta l .
2010). Drastic changes in carbohydrate determinants facili-
tating these events are often caused by the alteration in gene
expression levels of glycosyltransferases. Consistent with the
Knudson’s two-hit hypothesis, promoter hypermethylation of
a glycogene could be an event that is along with allelic loss
or loss of heterozigosity causing this alteration (Kim et al.
2008). Indeed, both occurrences were responsible for the
downregulation of A/B glycosyltransferases, which in turn
resulted in a decreased expression of blood group A and B
antigens in tumours (Dabelsteen and Gao 2005). The role of
promoter methylation was further confirmed by treating
gastric and colon cancer celllines witha methylation inhibitor
5-aza-2’-deoxycytidine (5-aza-dC) that resulted in the upre-
gulation of α1,3-N-acetylgalactosaminyltransferase, an en-
zyme responsible for the expression of the A determinant
(Kawamura et al. 2008). Other examples of the regulation of
glycogene expression by promoter methylation include the
N-acetylglucosaminyltransferases GnT-IV a and GnT-IVb in
pancreas (Ide et al. 2006), the α-1,3/4 fucosyltransferase
Fig. 2 Glycan structures inte-
grate the activity of hundreds
of genes. An example of
structural variations in IgG gly-
cans is presented. Initial
GlcNAc2Man3GlcNAc2 structure
(red square)c a nb em o d i f i e d
by the addition of bisecting
GlcNAc (GnTIII), fucose (FUT8)
or galactose (GalT). These
resulting structures can further be
modified by the activity of the
same enzymes or by the addition
of the sialic acid (SiaT)
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and FUT7 in leukocytes (Syrbe et al. 2004).
Around half of the known human genes contain CpG-rich
sites within their promoter regions including many glyco-
genes. One of the more recent studies undertook more
extensive analyses concerning the involvement of DNA
methylation in the regulation offucosylation in several cancer
cell lines with relatively low fucosylation levels. Interestingly,
treatment with a methyltransferase inhibitor zebularine
resulted in the upregulation of the expression of
fucosylation-relatedgenes,includingFut4,GDP-fucosetrans-
porter and FX genes, leading to an increase in the global
fucosylation level (Moriwaki et al. 2010). Still, the presence
of a CpG island in a gene promoter does not necessarily
imply a control of gene expression by DNA methylation, as
shown for fucosyltransferase genes FUT1 and FUT2 whose
expression levels were not recovered following the treatment
with 5-aza-dC (Kawamura et al. 2008).
Another interesting observation came from studying the
increased expression of sialyl Lewis
a antigen in cancers of
the digestive organs, where it serves as a ligand for E-
selectin, thus mediating metastasis (Kannagi 1997). Avery
similar glycan epitope disialyl Lewis
a is preferentially
synthesized in normal epithelial cells by the action of
α2→6 sialyltransferase (ST6GalNAc6), which adds an
additional sialyl group to a sialyl Lewis
a glycan (Tsuchida
et al. 2003). Previously, the common strategy to explain an
enhanced synthesis of cancer-related glycans was to study a
potential increase in the levels of transcription of genes
involved in their synthesis (Ito et al. 1997). Surprisingly, in
this case, it was the downregulation of ST6GalNAc6 that
resulted in the overexpression of sialyl Lewis
a. A decrease
in the expression level was achieved by epigenetic
mechanisms as shown in cultured human colon cells where
following the treatment with butyrate, an inhibitor of
histone deacetylation, or 5-azacytidine, an inhibitor of
DNA methylation, the reexpression of disialyl Lewis
a was
induced (Miyazaki et al. 2004). This example argues in
favour of the dominance of the “incomplete synthesis” over
the “neosynthesis” concept in production of some complex
carbohydrate determinants. Accordingly, it was shown that
the downregulation of various glycogenes, involved in the
synthesis of normally expressed determinants in cancer cell
lines, occurs primarily by promoter methylation (Kawamura
et al. 2008), which could potentially result in the upregula-
tion of other cancer-associated carbohydrate antigens.
Nevertheless, complex glycans are often found in
malignant cells with high metastatic potential. These cells
are characterized by an increased expression of β1,6-
branched N-linked glycans, resulting from the upregulated
expression of GnT-V (also known as Mgat5) (Taniguchi et
al. 1999). These complex glycan structures are found on
differentproteins,includinganadhesionmoleculeE-cadherin,
which promote cell detachment and invasion (Dennis et al.
2002) and a tissue inhibitor of metalloproteinase-1 in human
colon cancer cells, increasing their metastatic potential (Kim
et al. 2008). The observed upregulation of the GnT -V
expression level was positively correlated to the expression
of a transcription factor ets-1 in various cancer cell lines (Ko
et al. 1999). On the other hand, glycan branching was shown
to be inhibited by the overexpression of GnT -III, thus
reducing the metastatic potential of cancer cells (Taniguchi
et al. 1999). Recently, we found the correlation between a
transcription factor hepatocyte nuclear factor 1A (HNF1A)
promoter methylation and the expression of complex
branched glycans (unpublished data). Thus, an intricate
network of various factors seems to be involved in the
synthesis of complex glycan structures. To elucidate a cell’s
capacity to synthesize a particular glycan, one needs to
understand the modes of regulating the expression of not
only glycogenes but of transcription factors and all other
glycan-related genes involved in the synthesis of a particular
glycan structure as well. Therefore, we believe future efforts
will be directed towards understanding the epigenetic control
of gene expression of all factors involved in glycan
synthesis, primarily through DNA methylation of promoter
sequences, but also in coordination with histone modification
marks of particular genomic regions.
Evolutional implications of the epigenetic regulation
of protein glycosylation
The variability of glycan structures within a particular
species and between different ones by far exceeds the
variability of proteins and other macromolecules. From the
evolutionary perspective, this seems very logical since
proteins perform specific tasks (enzymatic reaction, trans-
port, recognition, etc.) and a change in their structure or
activity might result in losing the ability to perform their
dedicated task. On the other hand, since glycans primarily
modulate the protein function they can vary much more
freely. The observed large variety in glycan structures might
be resulting from small alterations in structure and/or
regulation of different factors combined into a complex
pathway, which regulates glycosylation.
Therefore, while small differences between individual
genes can hardly account for the versatility of life forms,
the introduction of a slight modification in a pathway that
involves synergistic action of various factors could have
very significant consequences to the physiology of a cell. A
good comparison might be drawn with how the traffic
functions in a big city; a slight modification in the traffic
light timing on several main crossings could result in a
disruption of smooth traffic and finally complete chaos. On
the other hand, it could also lead to a creation of novel,
Clin Epigenet (2011) 2:425–432 429alternative passageways. Therefore, in the context of living
cells, there is a need for precise coordination of activity of
all the factors involved in cellular processes. However, the
alteration introduced by environmental factors might prove
to be beneficial for a cell or an organism in a given
environment. While changes in protein structures may arise
only as a consequence of mutations that irreversibly alter
genetic information and can be validated only in the second
generation,changesinglycanstructuresarereversibleandcan
be repeatedly evaluated within the same organism, the
example of which comes from a study of crosstalk between
intestinal glycans and commensal intestinal bacteria (Hooper
and Gordon 2001).
While on an evolutionary scale in order to improve their
phenotypes in response to a given environment, higher
organisms are subject to genetic mutations, on a lifetime
scale they use much more sophisticated tools to adapt to
environmental changes—and these include an epigenetic
regulation of gene expression. Nutritional factors such as
folate methyl donors, inorganic contaminants, drugs,
endocrine disruptors, phytoestrogens, chemicals used in
agriculture, etc., are the environmental factors, which can
quickly influence cellular enzymatic processes. This occurs
due to alterations of a gene expression status of relevant
genes in a specific cell type, which is then inherited through
numerous cell cycles. It is easily envisioned that an
epigenetic modulation of glycogenes expression levels
resulting in the synthesis of more adapt glycan structures
could render the organism more fit for survival in a given
environment (food sources, specific commensal or patho-
genic microorganisms etc.).
The evolutionary changes in glycan structures have
particularly been studied in the context of host–pathogen
interactions. It seems that host organisms induce structural
changes in their glycan repertoire in order to evade an
invasion by pathogenic microbes (V arki 2006). This often
occurs by introducing a mutation that irreversibly inacti-
vates one or more genes involved along the glycan
assembly line. Advantageously for the host, this might lead
to a prevention of recognition by the pathogen. Neverthe-
less, it can potentially result in a complete loss of the
glycan(s) with important endogenous function(s) (Bishop
and Gagneux 2007). In order to avoid potentially detri-
mental consequences for the host organism, alternative
mechanisms might have evolved, which would allow a
more subtle control by shutting down the glycogene
expression levels in case of a pathogen invasion and
reestablishing their activity afterwards. Here, the reversibil-
ity and plasticity of the epigenetics modes of controlling
gene expression may prove to be more advantageous than
genetic mechanisms involving changes in the DNA
sequence itself. Favouring this hypothesis is the finding
that many glycosyltransferase genes are conserved in
between different species (Esko and Selleck 2002;
Harduin-Lepers et al. 2005), even though the same
conserved glycoprotein can carry different glycan structures
(Gagneux and V arki 1999).
The Jean-Baptiste Lamarck’s idea arguing that character-
isticsacquiredduringanindividual’slifetimecanbepassedon
totheoffspringhasnowadaysbeenreconsideredinthelightof
epigenetics. Over the past decade, it has become increasingly
clear that environmental factors, such as diet or stress, can
have biological consequences that are transmitted to an
offspring without a single change in a gene sequences. The
epigenetics, by definition, involves various modes of reading
the genetic information. When in a population a new mode
arises,itwouldaswellbesubject tothe evolutionarypressure,
including natural selection, genetic drift, etc., leading to its
potential heritability. Even though the epigenetic transgenera-
tional inheritance is still an insufficiently understood process
(Rakyan and Beck 2006;R i c h a r d s2006), there are examples
favouring its existence. It has been shown that some
epialleles can be transmitted to the offspring due to the
incomplete erasure of cytosine methylation marks during the
genome-wide resetting, which normally occurs during the
early development in mammals (Morgan et al. 2005). It is
tempting to speculate that the transmission of an acquired
epigenetic regulatory status of glycogenes to a germ cell
could be an essential evolutionary mechanism, which would
enable adaptation of complex organisms to environmental
changes, while preserving the precious genetic heritage.
Whether this would entail skipping the epigenetic re-setup
during the early development and in gametogenesis, or
whether some other mechanisms might be at hand, remains
to be elucidated.
Acknowledgements Work in authors’ laboratories is supported by
grants #309-0061194-2023 (to G.L.) and #119-1191196-1224 (to V .Z.)
from the Croatian Ministry of Science, Education and Sport, and by
FP7-EuroGlycoArrays and FP7-GlycoBioM grants from the European
Community.
Conflicts of interest None
References
Abbott KL, Nairn A V , Hall EM, Horton MB, McDonald JF, Moremen
KW, Dinulescu DM, Pierce M (2008) Focused glycomic analysis
of the N-linked glycan biosynthetic pathway in ovarian cancer.
Proteomics 8:3210–3220
Alavi A, Axford JS (2008) Sweet and sour: the impact of sugars on
disease. Rheumatology (Oxford) 47:760–770
Anthony RM, Ravetch JV (2010) A novel role for the IgG Fc glycan:
the anti-inflammatory activity of sialylated IgG Fcs. J Clin
Immunol 30(Suppl 1):S9–S14
Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC,
Ravetch JV (2008) Recapitulation of IVIG anti-inflammatory
activity with a recombinant IgG Fc. Science 320:373–376
430 Clin Epigenet (2011) 2:425–432Apweiler R, Hermjakob H, Sharon N (1999) On the frequency of
protein glycosylation, as deduced from analysis of the SWISS-
PROT database. Biochim Biophys Acta 1473:4–8
Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2007) The
impact of glycosylation on the biological function and structure
of human immunoglobulins. Annu Rev Immunol 25:21–50
Axford JS (1999) Glycosylation and rheumatic disease. Biochim
Biophys Acta 1455:219–229
Bishop JR, Gagneux P (2007) Evolution of carbohydrate antigens—
microbial forces shaping host glycomes? Glycobiology 17:23R–
34R
Brockhausen I, Schutzbach J, Kuhns W (1998) Glycoproteins and
their relationship to human disease. Acta Anat 161:36–78
Brown RS (2009) Autoimmune thyroid disease: unlocking a complex
puzzle. Curr Opin Pediatr 21:523–528
Calo D, Kaminski L, Eichler J (2010) Protein glycosylation in
Archaea: sweet and extreme. Glycobiology 20:1065–1076
Crocker PR, Paulson JC, V arki A (2007) Siglecs and their roles in the
immune system. Nat Rev Immunol 7:255–266
Cummings RD (2009) The repertoire of glycan determinants in the
human glycome. Mol Biosyst 5:1087–1104
Dabelsteen E, Gao S (2005) ABO blood-group antigens in oral cancer.
J Dent Res 84:21–28
Dalziel M, Whitehouse C, McFarlane I, Brockhausen I, Gschmeissner S,
Schwientek T, Clausen H, Burchell JM, Taylor-Papadimitriou J
(2001) The relative activities of the C2GnT1 and ST3Gal-I
glycosyltransferases determine O-glycan structure and expression of
atumor-associatedepitope onMUC1. J BiolChem276:11007–11015
Dennis JW , Pawling J, Cheung P , Partridge E, Demetriou M (2002) UDP-
N-acetylglucosamine:alpha-6-D-mannoside beta1,6N-acetylgluco-
saminyltransferase V (Mgat5) deficient mice. Biochim Biophys
Acta 1573:414–422
Dennis JW, Lau KS, Demetriou M, Nabi IR (2009) Adaptive
regulation at the cell surface by N-glycosylation. Traffic
10:1569–1578
Dhiman N, Haralambieva IH, Kennedy RB, Vierkant RA, O’Byrne
MM, Ovsyannikova IG, Jacobson RM, Poland GA (2010) SNP/
haplotype associations in cytokine and cytokine receptor genes
and immunity to rubella vaccine. Immunogenetics 62:197–210
DrickamerK,TaylorME(1998)Evolvingviewsofproteinglycosylation.
Trends Biochem Sci 23:321–324
Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation-
potential for therapeutics and diagnostics. Nat Rev Drug Discov
4:477–488
Esko JD, Selleck SB (2002) Order out of chaos: assembly of ligand
binding sites in heparan sulfate. Annu Rev Biochem 71:435–471
Freeze HH (2002) Human disorders in N-glycosylation and animal
models. Biochim Biophys Acta 1573:388–393
Freeze HH (2006) Genetic defects in the human glycome. Nat Rev
Genet 7:537–551
Fuster MM, Esko JD (2005) The sweet and sour of cancer: glycans as
novel therapeutic targets. Nat Rev Cancer 5:526–542
Gagneux P , V arki A (1999) Evolutionary considerations in relating
oligosaccharide diversity to biological function. Glycobiology
9:747–755
Gornik O, Lauc G (2008) Glycosylation of serum proteins in
inflammatory diseases. Dis Markers 25:267–278
Gornik O, Wagner J, Pučić M, Knežević A, Redžić I, Lauc G (2009)
Stability of N-glycan profiles in human plasma. Glycobiology
19:1547–1553
Haeuptle MA, Hennet T (2009) Congenital disorders of glycosylation:
an update on defects affecting the biosynthesis of dolichol-linked
oligosaccharides. Hum Mutat 30:1628–1641
Harduin-Lepers A, Mollicone R, Delannoy P , Oriol R (2005) The
animal sialyltransferases and sialyltransferase-related genes: a
phylogenetic approach. Glycobiology 15:805–817
Helenius A, Aebi M (2001) Intracellular functions of N-linked
glycans. Science 291:2364–2369
Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection
and control of the cell surface. Nat Rev Cancer 4:45–60
Hooper LV , Gordon JI (2001) Glycans as legislators of host-microbial
interactions: spanning the spectrum from symbiosis to pathoge-
nicity. Glycobiology 11:1R–10R
Ide Y , Miyoshi E, Nakagawa T, Gu J, Tanemura M, Nishida T, Ito T,
Yamamoto H, Kozutsumi Y , Taniguchi N (2006) Aberrant
expression of N-acetylglucosaminyltransferase-IV a and IVb
(GnT-IV a and b) in pancreatic cancer. Biochem Biophys Res
Commun 341:478–482
Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N,
Wakitani M, Yano K, Shitara K, Satoh M (2006) Nonfucosylated
therapeutic IgG1 antibody can evade the inhibitory effect of
serum immunoglobulin G on antibody-dependent cellular cyto-
toxicity through its high binding to FcgammaRIIIa. Clin Cancer
Res 12:2879–2887
Ito H, Hiraiwa N, Sawada-Kasugai M, Akamatsu S, Tachikawa T,
Kasai Y , Akiyama S, Ito K, Takagi H, Kannagi R (1997) Altered
mRNA expression of specific molecular species of fucosyl- and
sialyl-transferases in human colorectal cancer tissues. Int J
Cancer 71:556–564
Kannagi R (1997) Carbohydrate-mediated cell adhesion involved in
hematogenous metastasis of cancer. Glycoconj J 14:577–584
Kawamura YI, Toyota M, Kawashima R, Hagiwara T, Suzuki H, Imai
K, Shinomura Y , Tokino T, Kannagi R, Dohi T (2008) DNA
hypermethylation contributes to incomplete synthesis of carbo-
hydrate determinants in gastrointestinal cancer. Gastroenterology
135:142–151
Kim YS, Hwang SY , Kang HY , Sohn H, Oh S, Kim JY , Yoo JS, Kim
YH, Kim CH, Jeon JH, Lee JM, Kang HA, Miyoshi E, Taniguchi
N, Yoo HS, Ko JH (2008) Functional proteomics study reveals
that N-Acetylglucosaminyltransferase V reinforces the invasive/
metastatic potential of colon cancer through aberrant glycosyla-
tion on tissue inhibitor of metalloproteinase-1. Mol Cell
Proteomics 7:1–14
Knežević A, Polašek O, Gornik O, Rudan I, Campbell H, Hayward C,
Wright A, Kolčić I, O’Donoghue N, Bones J, Rudd PM, Lauc G
(2009) V ariability, heritability and environmental determinants of
human plasma N-glycome. J Proteome Res 8:694–701
Knežević A, Gornik O, Polašek O, Pučić M, Novokmet M, Redžić I,
Rudd PM, Wright AF, Campbell H, Rudan I, Lauc G (2010)
Effects of aging, body mass index, plasma lipid profiles, and
smoking on human plasma N-glycans. Glycobiology 20:959–969
Ko JH, Miyoshi E, Noda K, Ekuni A, Kang R, Ikeda Y , Taniguchi N
(1999) Regulation of the GnT-V promoter by transcription factor
Ets-1 in various cancer cell lines. J Biol Chem 274:22941–22948
Lauc G, Zoldos V (2010) Protein glycosylation—an evolutionary
crossroad between genes and environment. Mol Biosyst 6:2373–
2379
Lauc G, Rudan I, Campbell H, Rudd PM (2010) Complex genetic
regulation of protein glycosylation. Mol Biosyst 6:329–335
Lebrilla CB, An HJ (2009) The prospects of glycan biomarkers for the
diagnosis of diseases. Mol Biosyst 5:17–20
Lee RT, Lauc G, Lee YC (2005) Glycoproteomics: protein modifica-
tions for versatile functions. EMBO Rep 6:1018–1022
Marek KW, Vijay IK, Marth JD (1999) A recessive deletion in the
GlcNAc-1-phosphotransferase gene results in peri-implantation
embryonic lethality. Glycobiology 9:1263–1271
Marth JD, Grewal PK (2008) Mammalian glycosylation in immunity.
Nat Rev Immunol 8:874–887
Miyazaki K, Ohmori K, Izawa M, Koike T, Kumamoto K, Furukawa
K, Ando T, Kiso M, Yamaji T, Hashimoto Y , Suzuki A, Y oshida
A, Takeuchi M, Kannagi R (2004) Loss of disialyl Lewis(a), the
ligand for lymphocyte inhibitory receptor sialic acid-binding
Clin Epigenet (2011) 2:425–432 431immunoglobulin-like lectin-7 (Siglec-7) associated with increased
sialyl Lewis(a) expression on human colon cancers. Cancer Res
64:4498–4505
Morgan HD, Santos F, Green K, Dean W, Reik W (2005) Epigenetic
reprogramming in mammals. Hum Mol Genet 14(Spec No 1):
R47–R58
MoriwakiK, Narisada M, Imai T, Shinzaki S and Miyoshi E (2010) The
effect of epigenetic regulation of fucosylation on TRAIL-induced
apoptosis. Glycoconj J 27(7–9):649–659
Nairn A V , York WS, Harris K, Hall EM, Pierce JM, Moremen KW
(2008) Regulation of glycan structures in animal tissues:
transcript profiling of glycan-related genes. J Biol Chem
283:17298–17313
Nimmerjahn F, Ravetch JV (2008) Anti-inflammatory actions of
intravenous immunoglobulin. Annu Rev Immunol 26:513–533
Ohtsubo K, Marth JD (2006) Glycosylation in cellular mechanisms of
health and disease. Cell 126:855–867
Ovsyannikova IG, Haralambieva IH,Dhiman N, O’Byrne MM, Pankratz
VS, Jacobson RM, Poland GA (2010) Polymorphisms in the
vitamin A receptor and innate immunity genes influence the
antibody response to rubella vaccination. J Infect Dis 201:207–213
Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P ,
Granovsky M, Nabi IR, Wrana JL, Dennis JW (2004) Regulation
of cytokine receptors by Golgi N-glycan processing and
endocytosis. Science 306:120–124
PotapenkoIO, HaakensenVD,LudersT,HellandA,Bukholm I, Sorlie T,
Kristensen VN, Lingjaerde OC, Borresen-Dale AL (2010) Glycan
gene expression signatures in normal and malignant breast tissue;
possible role in diagnosis and progression. Mol Oncol 4:98–118
Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ,
Baeuerle PA, Prang NS (2006) High concentrations of therapeutic
IgG1 antibodies are needed to compensate for inhibition of
antibody-dependent cellular cytotoxicity by excess endogenous
immunoglobulin G. Mol Immunol 43:1183–1193
Pučić M, Pinto S, Novokmet M, Knežević A, Gornik O, Polašek O,
Vlahoviček K, Wei W, Rudd PM, Wright AF, Campbell H, Rudan
I, Lauc G (2010) Common aberrations from normal human N-
glycan plasma profile. Glycobiology 20:970–975
Rakyan VK, Beck S (2006) Epigenetic variation and inheritance in
mammals. Curr Opin Genet Dev 16:573–577
Reis CA, Osorio H, Silva L, Gomes C, David L (2010) Alterations in
glycosylation as biomarkers for cancer detection. J Clin Pathol
63:322–329
Richards EJ (2006) Inherited epigenetic variation—revisiting soft
inheritance. Nat Rev Genet 7:395–401
Serpa J, Mesquita P , Mendes N, Oliveira C, Almeida R, Santos-Silva
F, Reis CA, LePendu J, David L (2006) Expression of Lea in
gastric cancer cell lines depends on FUT3 expression regulated
by promoter methylation. Cancer Lett 242:191–197
Shields RL, Lai J, Keck R, O’Connell LY , Hong K, Meng YG, Weikert
SH, Presta LG (2002) Lack of fucose on human IgG1 N-linked
oligosaccharide improves binding to human Fcgamma RIII and
antibody-dependent cellular toxicity. J Biol Chem 277:26733–
26740
Skropeta D (2009) The effect of individual N-glycans on enzyme
activity. Bioorg Med Chem 17:2645–2653
Syrbe U, Jennrich S, Schottelius A, Richter A, Radbruch A, Hamann
A (2004) Differential regulation of P-selectin ligand expression
in naive versus memory CD4+ T cells: evidence for epigenetic
regulation of involved glycosyltransferase genes. Blood
104:3243–3248
Taniguchi N, Miyoshi E, Ko JH, Ikeda Y , Ihara Y (1999) Implication
of N-acetylglucosaminyltransferases III and V in cancer: gene
regulation and signaling mechanism. Biochim Biophys Acta
1455:287–300
Taniguchi N, Honke K, Fukuda M (2002) Handbook of glycosyltrans-
ferases and related genes. Springer, Heidelberg
Ten Hagen KG, Fritz TA, Tabak LA (2003) All in the family: the
UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases.
Glycobiology 13:1R–16R
Tsuchida A, Okajima T, Furukawa K, Ando T, Ishida H, Yoshida A,
Nakamura Y , Kannagi R, Kiso M (2003) Synthesis of disialyl
Lewis a (Le(a)) structure in colon cancer cell lines by a
sialyltransferase, ST6GalNAc VI, responsible for the synthesis
of alpha-series gangliosides. J Biol Chem 278:22787–22794
V arki A (1993) Biological roles of oligosaccharides: all of the theories
are correct. Glycobiology 3:97–130
V arki A (2006) Nothing in glycobiology makes sense, except in the
light of evolution. Cell 126:841–845
V arki A, Angata T (2006) Siglecs—the major subfamily of I-type
lectins. Glycobiology 16:1R–27R
Weerapana E, Imperiali B (2006) Asparagine-linked protein glycosyla-
tion: from eukaryotic to prokaryotic systems. Glycobiology
16:91R–101R
Zoldoš V , Grgurević S, Lauc G (2010) Epigenetic regulation of protein
glycosylation. Biomol Concepts 1:253–261
432 Clin Epigenet (2011) 2:425–432